Exparel Access Issues: What Providers and Prescribers Need to Know in 2026

As of 2026, Exparel (bupivacaine liposome injectable suspension) does not appear on the FDA's active drug shortage database. For surgeons, anesthesiologists, and CRNAs, this means supply-chain disruptions are not the primary concern — but access challenges for patients remain real and multifactorial. This guide examines the current landscape for Exparel, covering formulary dynamics, the NOPAIN Act's impact on reimbursement, evidence debates, and practical steps providers can take to help patients access this non-opioid analgesic.

Current Supply Status

Pacira BioSciences has maintained consistent commercial availability of Exparel since its U.S. launch in April 2012. The product is manufactured and distributed through a single-source supply chain. The FDA has not declared a shortage, and no significant national supply disruptions are currently reported. Providers should be able to procure Exparel through standard hospital distributors (e.g., Cardinal Health, McKesson, Medline) without supply-related barriers.

However, individual hospital formulary restrictions or purchasing contract changes may limit availability at specific facilities. If your facility has recently removed Exparel from formulary or restricted its use, Pacira's PaciraConnect program may be able to help navigate coverage and reimbursement support.

Formulary Access: The Primary Barrier to Patient Access

The most significant barrier to Exparel access is cost-driven formulary restriction. A single 266 mg/20 mL vial carries an average wholesale price of approximately $378–$444, compared to $2–$8 for a generic bupivacaine HCl vial. This cost differential has prompted many hospital P&T committees to restrict Exparel to specific high-value procedures (e.g., total joint arthroplasty, thoracic surgery, shoulder procedures) or to require departmental justification for use.

For providers who believe Exparel is clinically appropriate for a patient in a procedure category not currently on formulary, options include:

• Submitting a formulary exception request to your hospital P&T committee
• Documenting clinical rationale in the patient's chart (e.g., opioid use disorder, prior opioid-related adverse events, high-risk procedure for postoperative pain)
• Engaging the Pacira BioSciences medical affairs team for institutional support

The NOPAIN Act: A Reimbursement Game-Changer in 2025–2026

Effective January 1, 2025, the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act authorized CMS to make separate Medicare payment for FDA-approved non-opioid analgesic drugs or biologicals when used in the outpatient surgical setting. Exparel was specifically contemplated in this legislation as a qualifying drug.

Prior to the NOPAIN Act, Exparel used in ambulatory surgical centers or hospital outpatient departments was often bundled into the procedure reimbursement package — effectively making the facility absorb its cost with no additional payment. The NOPAIN Act changes this: facilities can now receive a separate add-on payment for Exparel when administered in qualifying outpatient settings. This makes it significantly more financially viable for ASCs and HOPDs to add Exparel to their formularies.

Action step for providers: If your facility has been restricting Exparel use due to reimbursement concerns for Medicare patients, revisit the formulary decision in light of NOPAIN Act payments. Engage your facility's coding and billing team to ensure they're capturing the add-on payment appropriately.

The Evolving Evidence Base

The clinical evidence for Exparel remains a subject of active debate. Early RCTs comparing Exparel to placebo demonstrated significant reductions in opioid consumption and pain scores over 72 hours. However, multiple subsequent meta-analyses comparing Exparel to plain bupivacaine or ropivacaine have found more modest or inconsistent advantages.

A 2023 meta-analysis found that liposomal bupivacaine statistically reduced rest pain scores at 24, 48, and 72 hours compared to long-acting local anesthetics, but the reduction was approximately 0.9 points on a 10-point scale — raising questions about clinical significance. However, in the context of ERAS protocols and multimodal analgesia, even small reductions in opioid consumption can have meaningful downstream effects on length of stay, patient satisfaction, and opioid-related adverse events.

The strongest evidence for Exparel's benefits remains in procedure-specific settings: total knee arthroplasty, total hip arthroplasty, thoracic surgery, and interscalene nerve blocks for shoulder procedures. Providers should individualize the risk-benefit analysis by procedure type rather than applying a blanket institutional policy.

Important Safety and Administration Reminders

For providers administering Exparel, key safety points include:

• No admixing with non-bupivacaine local anesthetics. Lidocaine, mepivacaine, and chloroprocaine can cause immediate release of bupivacaine from the liposomes. Wait at least 20 minutes after local administration of lidocaine before injecting Exparel.
• Maximum dose is 266 mg (one 20 mL vial). Do not exceed this single-dose limit.
• Use a 25-gauge or larger bore needle to preserve liposomal particle integrity.
• ISMP high-alert medication. Exparel's appearance is similar to propofol — ensure clear labeling and storage separation to prevent wrong-route errors.
• No repeat dosing within 72 hours of an infiltration and no other local anesthetics within 96 hours post-Exparel (unless clinically urgent with monitoring).

Helping Patients Navigate Post-Surgical Prescriptions

Postoperative patients often face challenges filling oral prescriptions for pain management medications at discharge. medfinder for providers is a paid service that calls pharmacies on behalf of your patients to locate in-stock medications near them, texting results directly to the patient. This service reduces discharge delays and patient frustration when take-home prescriptions are not readily available locally.

See also: How to Help Your Patients Find Exparel in Stock: A Provider's Guide for specific workflows and talking points.